Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence

Overview

The investigators are conducting a Stage 1 pilot feasibility study at McLean Hospital to develop and refine a Cognitive Behavioral Therapy (CBT) intervention. The investigators aim to develop a feasible 10-week integrated CBT intervention for the treatment of concurrent marijuana dependence and nicotine dependence. The investigators hypothesize that the CBT intervention, in conjunction with Nicotine Replacement Therapy (NRT) in the form of a transdermal nicotine patch, will reduce the use of marijuana and nicotine.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2011

Detailed Description

The investigators will conduct a Stage 1 pilot feasibility study at McLean Hospital to develop and refine a Cognitive Behavioral Therapy (CBT) intervention. Twelve subjects (50% female, ages 18-65) who meet Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria for both marijuana and nicotine dependence and seek treatment to stop using both marijuana and tobacco will receive individual CBT aimed at treating both disorders, as well as Nicotine Replacement Therapy (NRT) in the form of a transdermal nicotine patch. Subjects will start with a 21-mg nicotine patch for 6 weeks, followed by a taper to a 14-mg nicotine patch for 2 weeks and, finally, a 7-mg nicotine patch for 2 weeks. Others will start with a 14-mg patch for 8 weeks followed by a 7-mg patch for 2 weeks. All participants will receive 10 weeks of 1-hour weekly CBT with an experienced clinician. Follow-up visits, scheduled at 4, 6, 8, and 10 weeks, will evaluate of the durability of treatment effects on drug use and psychosocial outcomes.

Interventions

  • Behavioral: Cognitive Behavioral Therapy
    • individual CBT once weekly, 50 minutes, for 10 weeks
  • Drug: Nicotine Replacement Therapy
    • 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks

Arms, Groups and Cohorts

  • Experimental: Treatment
    • Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.

Clinical Trial Outcome Measures

Primary Measures

  • Cigarette Use
    • Time Frame: Baseline and 10 weeks
    • cigarettes per day
  • Cannabis Use
    • Time Frame: Baseline and 10 weeks
    • cannabis inhalations per day

Secondary Measures

  • Client Satisfaction Questionnaire (CSQ-8) at 10 Weeks
    • Time Frame: 10 weeks
    • The Client Satisfaction Questionnaire (CSQ-8) is a self-report instrument used to assess satisfaction with health services and it was used to assess participant satisfaction with the treatment during this 10 week study. Scores range from 8 – 32 with higher values indicating higher satisfaction.

Participating in This Clinical Trial

Inclusion Criteria

  • Age range 18-65 years – current DSM-IV cannabis dependence – current DSM-IV nicotine dependence – express a desire to quit cannabis and nicotine use within the next 30 days – daily use of ≥ 10 tobacco cigarettes – for women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy and additional pregnancy tests at weeks 4 and 8 – Expired breath carbon monoxide (CO) determination is greater than or equal to 7 ppm over ambient values Exclusion Criteria:

  • Current diagnosis of other drug or alcohol dependence (other than cannabis or nicotine) – recent (within 3 months) significant cardiac disease – current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder or significant current suicidal or homicidal thoughts – current use of bupropion – current NRT or other smoking cessation treatment – current CBT or other behavioral treatments for cessation of marijuana or tobacco smoking – current smokeless tobacco use – inability to read or write in English

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mclean Hospital
  • Collaborator
    • Harvard Medical School (HMS and HSDM)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kevin P. Hill, MD, MHS, Instructor in Psychiatry – Mclean Hospital
  • Overall Official(s)
    • Kevin P Hill, MD, MHS, Principal Investigator, Mclean Hospital

References

Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol. 2004 Jun;72(3):455-66. doi: 10.1037/0022-006X.72.3.455.

Hill, K.P., and Chang, G. Cognitive Behavioral Therapy and Nicotine Replacement for Smoking Cessation in Psychiatric Outpatients with Major Depression. Addictive Disorders and Their Treatment, 6: 67-72, 2007.

Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol. 1994 Feb;62(1):141-6. doi: 10.1037//0022-006x.62.1.141.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.